2025
Outcomes of Venovenous Extracorporeal Membrane Oxygenation for Pneumocystis jirovecii Pneumonia: A Multicenter Retrospective Case Series
Pulsipher A, Henry K, Vikram H, Gotway M, Cartin-Ceba R, Limper A, Lee A, Patel B, Miller B, Thompson E, Sen A, Ham K. Outcomes of Venovenous Extracorporeal Membrane Oxygenation for Pneumocystis jirovecii Pneumonia: A Multicenter Retrospective Case Series. Critical Care Explorations 2025, 7: e1296. PMID: 40758332, PMCID: PMC12324008, DOI: 10.1097/cce.0000000000001296.Peer-Reviewed Original ResearchConceptsPneumocystis jirovecii pneumoniaNon-HIV immunocompromised patientsVenovenous extracorporeal membrane oxygenationExtracorporeal membrane oxygenationVV-ECMOImmunocompromised patientsMembrane oxygenationRespiratory ECMO survival prediction scoreMulticenter retrospective case seriesSevere Pneumocystis jirovecii pneumoniaLife-threatening opportunistic infectionsAcute respiratory distress syndromeProlonged ECMO supportHIV-positive patientsRetrospective multicenter reviewSurvival prediction scoreRespiratory distress syndromeRetrospective case seriesPulmonary vasodilator useSalvage therapyRescue therapyVasodilator useECMO supportOpportunistic infectionsMultiorgan dysfunctionPositron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure
Bitar R, Zurita P, Martiniova L, Zurita A, Ravizzini G. Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure. Cancers 2025, 17: 1723. PMID: 40427220, PMCID: PMC12109795, DOI: 10.3390/cancers17101723.Peer-Reviewed Original ResearchProstate-specific membrane antigenProstate-specific antigenProstate cancerPositron emission tomographyPositron emission tomography radiotracersBiochemical recurrenceF-FDGUpregulation of amino acid transportersProstate-specific membrane antigen expressionBiochemical recurrence of prostate cancerInvestigate positron emission tomographySerum prostate-specific antigenRecurrence of prostate cancerPrimary treatment failurePSMA-targeted agentsSite of recurrencePrimary prostate cancerSalvage therapyF-fluciclovineLocalized diseaseTreatment failureDefinitive managementMembrane antigenInvestigational agentsRadionuclide therapy
2024
Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024
Engel B, Assis D, Bhat M, Clusmann J, Joostrenth, Gerussi A, Londoño M, Oo Y, Schregel I, Sebode M, Taubert R, collaborators T, Diseases T. Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024. JHEP Reports 2024, 7: 101265. PMID: 39897612, PMCID: PMC11783120, DOI: 10.1016/j.jhepr.2024.101265.Peer-Reviewed Original ResearchAutoimmune hepatitisInternational AIH GroupLiver transplant-free survivalAlternative first-lineCAR-T cellsRare chronic liver diseaseTransplant-free survivalDrug-induced autoimmunityChronic autoimmune responseEuropean Reference NetworkImmune-mediated diseasesChronic liver diseaseInitiative clinical trialsInflammatory bowel diseaseDecreased quality of lifeAIH patientsSalvage therapyRemission rateFirst-lineAIH groupT cellsStandard treatmentAutoimmune responseB cellsExpert centersAmerican Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer
Rodrigues G, Higgins K, Rimner A, Amini A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Iyengar P, Movsas B, Ning M, Park H, Wolf A, Simone C. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology 2024, 10: 799-806. PMID: 38602670, PMCID: PMC11665040, DOI: 10.1001/jamaoncol.2024.0294.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAmerican Radium Society Appropriate Use CriteriaAdvanced non-small cell lung cancerAmerican Radium SocietyAppropriate use criteriaNon-small cell lung cancerLA-NSCLCUnresectable LA-NSCLCCell lung cancerTreatment of locally advanced non-small cell lung cancerUnresectable locally advanced non-small cell lung cancerLung cancerIntensity-modulated radiotherapy techniqueDecades of clinical trialsPlatinum-based chemoradiationLung cancer radiotherapyEvidence-based consensus documentMultidisciplinary patient careEvidence-based guidelinesRadiotherapy techniquesSalvage therapyFractionation schedulesLocal recurrenceSystemic therapyCancer radiotherapyPhage Therapy for Respiratory Infections: Opportunities and Challenges
Khosravi A, Chen Q, Echterhof A, Koff J, Bollyky P. Phage Therapy for Respiratory Infections: Opportunities and Challenges. Lung 2024, 202: 223-232. PMID: 38772946, PMCID: PMC11570333, DOI: 10.1007/s00408-024-00700-7.Peer-Reviewed Original ResearchChronic lung infectionLung infectionRespiratory infectionsAntimicrobial resistancePhage therapyClinical trialsPhage therapy clinical trialsProgressive respiratory failureChronic respiratory infectionsPersonalized phage therapyAntimicrobial resistant infectionsPost-antibiotic eraPotential of phagesSalvage therapyAdjuvant therapyRespiratory failureDisease resolutionChronic respiratory diseasesTreatment efficacyTherapyTherapeutic potentialIncreased MortalityInfectionNovel antibioticsPhageONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Annapureddy D, Taylor J, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Facundo D, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER. Urologic Oncology Seminars And Original Investigations 2024, 42: s52-s53. DOI: 10.1016/j.urolonc.2024.01.160.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsive NMIBCMultinational cohort of patientsUpfront RCCancer-specific survivalInvasive bladder cancerRadical cystectomyOncological outcomesCohort of patientsAdequate BCGBCG therapyBCG-unresponsiveSalvage therapySpecific survivalBladder cancerMultinational cohortBCG-unresponsive NMIBC patientsAdequate BCG therapyBladder sparing therapyCombination intravesical therapyMaintenance BCG therapyNode positivity rateCompare oncologic outcomes
2023
Transcriptomic identification of genes expressed in invasive S. aureus diabetic foot ulcer infection
Agidigbi T, Kwon H, Knight J, Zhao D, Lee F, Oh I. Transcriptomic identification of genes expressed in invasive S. aureus diabetic foot ulcer infection. Frontiers In Cellular And Infection Microbiology 2023, 13: 1198115. PMID: 37434783, PMCID: PMC10332306, DOI: 10.3389/fcimb.2023.1198115.Peer-Reviewed Original ResearchConceptsDiabetic foot ulcersPeripheral blood mononuclear cellsHost immune responseActive infectionImmune responseDiabetic foot ulcer infectionsInfected diabetic foot ulcersFoot ulcer infectionsPatients 8 weeksIntravenous antibiotic therapyBlood mononuclear cellsWound healing statusDFU infectionsPBMC expressionSalvage therapyUlcer infectionDifferent time pointsAntibiotic therapyMajor complicationsSurgical treatmentFoot ulcersMononuclear cellsPotential intervention optionsSpecies-specific infectionTreatment responseTherapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series
Goodman R, Jung S, Quintos J, Johnson D. Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series. The Oncologist 2023, 28: e839-e842. PMID: 37338166, PMCID: PMC10485291, DOI: 10.1093/oncolo/oyad184.Peer-Reviewed Original ResearchConceptsMetastatic melanomaCase seriesCombination of anti-PD-1Multiple lines of systemic therapyCombined immune checkpoint inhibitorsLines of systemic therapyRefractory to standard treatmentTemozolomide combination therapyAnti-PD-1Immune checkpoint inhibitorsMetastatic melanoma patientsResponse to nivolumabCombination nivolumabLocal/regional therapyCheckpoint inhibitorsSalvage therapyTumor remissionMelanoma patientsSystemic therapyCombination therapySymptomatic improvementTargeted therapyChemotherapy agentsStandard treatmentTemozolomidePhase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Wu C, Braun D, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal For ImmunoTherapy Of Cancer 2023, 11: e004780. PMID: 36948504, PMCID: PMC10040058, DOI: 10.1136/jitc-2022-004780.Peer-Reviewed Original ResearchConceptsNivolumab/ipilimumabObjective response rateNon-clear cell renal cell carcinomaTreatment-naïve patientsCell renal cell carcinomaProgressive diseaseRenal cell carcinomaNivolumab monotherapyStable diseaseCell carcinomaAdvanced non-clear cell renal cell carcinomaMedian progression-free survivalTreatment-related adverse eventsDeath ligand 1 (PD-L1) expressionLigand 1 expressionPhase II studyProgression-free survivalWeeks of treatmentSymptomatic disease progressionEligible patientsSalvage therapyB patientsII studySalvage treatmentSarcomatoid featuresSurvival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar T, Atallah E, Shallis R, Saliba A, Patel A, Bewersdorf J, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg A, Abaza Y, Murthy G, Kota V, Litzow M. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia 2023, 37: 799-806. PMID: 36807649, DOI: 10.1038/s41375-023-01847-7.Peer-Reviewed Original ResearchConceptsEvent-free survivalAllo-HSCTOverall survivalChronic GVHDAllogeneic hematopoietic stem cell transplantAllogeneic stem cell transplantationMedian event-free survivalHematopoietic stem cell transplantAcute myeloid leukemia patientsMedian overall survivalPost allo-HSCTReduced intensity conditioningStem cell transplantStem cell transplantationLong-term outcomesMyeloid leukemia patientsMulti-center studyAcute graftComplete remissionHost diseaseSalvage therapyComplex cytogeneticsMyeloablative conditioningMedian ageCell transplant
2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leukemia & Lymphoma 2022, 64: 188-196. PMID: 36287540, PMCID: PMC9905301, DOI: 10.1080/10428194.2022.2136952.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaSalvage therapyIDH1/2 inhibitorsIDH2 inhibitorsMyeloid leukemiaResponse rateRefractory acute myeloid leukemiaEffective salvage therapyLow-dose cytarabineMedian overall survivalRetrospective cohort studyOverall response rateLow response rateCohort studyOverall survivalAML patientsTreatment optionsFLT3 inhibitorsITD mutationPatientsTherapyFLT3Little dataVenetoclaxInhibitorsAML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)
Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia 2022, 22: s209-s210. DOI: 10.1016/s2152-2650(22)01214-9.Peer-Reviewed Original ResearchOverall response rateAcute myeloid leukemiaMorphologic leukemia-free stateOverall survivalComplete responseIDH2 inhibitorsMedian OSPartial remissionTargeted therapyEffective salvage therapyIncomplete count recoveryMedian overall survivalShorter median OSRetrospective cohort studyShorter overall survivalAcademic cancer centerFLT3-ITD mutationAlternative therapeutic strategiesSalvage therapyCohort studyCount recoveryInhibitor therapyTargeted agentsClinical efficacyCancer Center
2021
Mechanical Cardiac Circulatory Support: an Overview of the Challenges for the Anesthetist
Notarianni A, Tickoo M, Bardia A. Mechanical Cardiac Circulatory Support: an Overview of the Challenges for the Anesthetist. Current Anesthesiology Reports 2021, 11: 421-428. PMID: 34611458, PMCID: PMC8484296, DOI: 10.1007/s40140-021-00486-x.Peer-Reviewed Original ResearchExtracorporeal membrane oxygenationSalvage therapyEnd-stage heart failureMechanical circulatory support devicesAcute myocardial infarctionCirculatory support devicesVentricular assist deviceECMO utilizationPerioperative managementAnesthetic managementBalloon pumpHeart failureMembrane oxygenationCardiopulmonary supportDestination therapyMyocardial infarctionAnesthetic supportRecent FindingsUseMCS devicesAssist deviceHemodynamic principlesPatientsManagement guidelinesTherapySupport devicesVenetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAllogeneic hematopoietic cell transplantAllo-HCTHematopoietic cell transplantSalvage therapyMyelodysplastic syndromeCell transplantMemorial Sloan-Kettering Cancer CenterHigh-risk myelodysplastic syndromeSecond allo-HCTSalvage treatment optionOverall response rateMedian followMedian OSVenetoclax therapyRetrospective studyCancer CenterTreatment optionsOS estimatesMyeloid leukemiaPatientsResponse rateTherapyTransplantMonthsRuxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database
Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Mesa R, Yacoub A, Hoffman R, Moshier E, Zubizarreta N, Mascarenhas J. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research 2021, 109: 106629. PMID: 34082375, DOI: 10.1016/j.leukres.2021.106629.Peer-Reviewed Original ResearchConceptsMulti-institutional databaseRuxolitinib discontinuationPolycythemia veraLarge multi-institutional databaseAvailable salvage therapiesDiscontinuation of ruxolitinibTreatment of patientsFurther therapeutic developmentLast followSalvage therapyCytoreductive therapyAdverse eventsPatient characteristicsThrombotic eventsTreatment initiationSimilar patientsDisease characteristicsDismal outcomeFavorable outcomeSalvage strategyPV patientsDiscontinuationInterferon αPatientsRuxolitinibPostoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).
Yu Y, Schöder H, Kang J, McBride S, Tsai C, Chen L, Zakeri K, Gelblum D, Boyle J, Cracchiolo J, Cohen M, Singh B, Ganly I, Patel S, Michel L, Dunn L, Pfister D, Wong R, Riaz N, Lee N. Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC). Journal Of Clinical Oncology 2021, 39: 6060-6060. DOI: 10.1200/jco.2021.39.15_suppl.6060.Peer-Reviewed Original ResearchPostoperative PET/CTIntermediate risk factorsSquamous cell carcinomaHigh-risk factorsPET/CTPT3-4 diseasePositive surgical marginsEarly recurrenceSurgical marginsExtranodal extensionLymphovascular invasionPerineural invasionRisk factorsOral cavityPostoperative radiotherapyOverall survivalPostoperative radiationPET/CT planningDistant metastasis-free survivalImproved disease-free survivalClinicopathologic risk factorsClose surgical marginsDisease-free survivalSalvage therapyDistant recurrencePhase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).
Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Hawley J, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Wu C, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B). Journal Of Clinical Oncology 2021, 39: 4510-4510. DOI: 10.1200/jco.2021.39.15_suppl.4510.Peer-Reviewed Original ResearchProgressive diseaseStable diseaseGrade 3Advanced non-clear cell renal cell carcinomaGrade 3 treatment-related adverse eventsNon-clear cell renal cell carcinomaTreatment-related adverse eventsMedian age 63Symptomatic progressive diseasePD-L1 statusPhase II studyTreatment-naïve patientsCell renal cell carcinomaWk of treatmentRenal cell carcinomaClear cell RCCCorrelative studiesAdvanced nccRCCEligible ptsUnclassified histologyMedian PFSSalvage therapyII studySalvage treatmentSarcomatoid featuresRe: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010
Kim S, Shin J, Shoag J. Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010. European Urology 2021, 80: e14. PMID: 33941402, DOI: 10.1016/j.eururo.2021.04.011.Peer-Reviewed Original ResearchThree-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Journal For ImmunoTherapy Of Cancer 2021, 9: e002478. PMID: 33879601, PMCID: PMC8061836, DOI: 10.1136/jitc-2021-002478.Peer-Reviewed Original ResearchConceptsProgression-free survivalMerkel cell carcinomaSalvage therapyStable diseaseCell carcinomaBaseline Eastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group performance statusAnti-programmed death-1 therapyCell death-1 pathway inhibitorsDeath-1 pathway inhibitorsDurable progression-free survivalFirst-line pembrolizumab therapyMedian progression-free survivalMulticenter phase II trialRefractory Merkel cell carcinomaTumor progressionAdvanced Merkel cell carcinomaMedian response durationFirst-line pembrolizumabPhase II trialProportion of patientsInitial disease progressionThree-year survivalDurable tumor regressionOverall response rateManagement of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP, Zeidan AM. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon? Best Practice & Research Clinical Haematology 2021, 34: 101245. PMID: 33762100, DOI: 10.1016/j.beha.2021.101245.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHigh-risk myelodysplastic syndromeHMA failureMyelodysplastic syndromeAgent azacitidineSalvage therapyNovel immune checkpoint inhibitorsEffective salvage therapyBCL-2 inhibitor venetoclaxCommon clinical dilemmaManagement of patientsStandard of careRationale drug developmentCheckpoint inhibitorsFrontline therapyMost patientsComplete responseMDS patientsFrontline settingFrontline treatmentShorter survivalClinical dilemmaInhibitor venetoclaxClinical testingPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply